Glycopyrrolate Tablets Recalled for Failed Impurities and Degradation Specifications
Glycopyrrolate tablets distributed nationwide are being recalled due to failed impurities and degradation specifications. Patients with affected lots should discontinue use and consult their healthcare provider.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: The recall addresses a pharmaceutical quality control failure (impurities and degradation) in a Class II recall with no reported illnesses or injuries. This represents a risk-of-harm product where injury has not yet been reported, meeting the rubric criteria for a High severity rating.
Plain-English summary
Aurolife Pharma, LLC is recalling Glycopyrrolate Tablets, USP, 1 mg. The recall affects 7,344 bottles distributed nationwide in the United States and Puerto Rico.
The recall was initiated due to the failure of certain batches to meet impurities and degradation specifications required for pharmaceutical products.
Patients and healthcare providers with Glycopyrrolate from lots 01422002A1 (expiration 12/2023) and 01421078A3 (expiration 09/2023) should discontinue use. Patients should contact their healthcare provider or pharmacy to ensure continuity of care and obtain a replacement supply if needed.
The recalled product
- Product
- GLYCOPYRROLATE (GLYCOPYRROLATE)
- Brand
- GLYCOPYRROLATE
- Manufacturer
- Aurolife Pharma, LLC
- Category
- Drug
- Hazard
- Affected units
- 7,344
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Lots: 01422002A1
- Expiry: 12/2023
- 01421078A3
- Expiry: 09/2023
UPCs (1)
- 0313107014017
Distribution
Related recalls
Same brand · GLYCOPYRROLATE
- ModerateGlycopyrrolate Oral Solution Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-29
- ModerateGlycopyrrolate Injection Recall Due to Hair Contamination
FDA (Drugs) · 2026-07-29
- ModerateGlycopyrrolate oral solution recalled after failing impurity and degradation specifications
FDA (Drugs) · 2026-02-04
- ModerateGlycopyrrolate Tablets Recalled Due to Failed Impurities and Degradation Specifications
FDA (Drugs) · 2023-06-28
- ModerateGlycopyrrolate Injection Vials Recalled Due to Labeling Mix-up
FDA (Drugs) · 2023-06-14
Same manufacturer · Aurolife Pharma, LLC
See all →- HighGlycopyrrolate Tablets Recalled Due to Glass Pieces in Sealed Bottles
FDA (Drugs) · 2022-04-06
- SevereAurolife Pharma Recalls Fexofenadine Hydrochloride Tablets Due to Impurity Failures
FDA (Drugs) · 2019-09-25
- SevereAurolife Recalls Fexofenadine Tablets Due to Impurity Failures
FDA (Drugs) · 2019-09-25
- SevereAurolife Recalls Fexofenadine Hydrochloride Tablets Due to Impurity Failures
FDA (Drugs) · 2019-09-25
- SevereAurolife Pharma Recalls Fexofenadine HCL Tablets Due to Impurity Failures
FDA (Drugs) · 2019-09-25
Same hazard · impurities
See all →- LowDabigatran Etexilate Capsules Recalled Due to Impurity Specification Failure
FDA (Drugs) · 2026-08-05
- ModerateMethohexital Sodium for Injection Recalled for Failed Impurities and Degradation Specifications
FDA (Drugs) · 2026-07-15
- ModerateMethohexital Sodium 100 mg/10 mL Compounded Drug Recalled Nationwide
FDA (Drugs) · 2026-07-15
- LowFexofenadine Hydrochloride Tablets 180 mg Recalled for Impurities
FDA (Drugs) · 2026-07-08
- ModerateAlyacen 7/7/7 birth control tablets failed total impurities specification
FDA (Drugs) · 2026-06-24